To date, several studies sought to assess the risk of melanoma and non-melanoma skin cancer (NMSC) in patients treated with biologics and found that TNF-α inhibitors may increase this risk [7,8]. This evidence concerns the gene TNF and non-melanoma skin carcinoma.